- Trials with a EudraCT protocol (24)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
24 result(s) found for: Rapid influenza diagnostic test.
Displaying page 1 of 2.
EudraCT Number: 2006-003284-31 | Sponsor Protocol Number: NV20236 | Start Date*: 2006-12-18 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: An open label multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in children | |||||||||||||
Medical condition: Seasonal prophylaxis of influenza in immunocompromised subjects | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002468-24 | Sponsor Protocol Number: NV20234 | Start Date*: 2008-02-13 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A double-blind, randomized, stratified, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenza | |||||||||||||
Medical condition: To investigate the optimal therapy for influenza in immunocompromised transplant recipients. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) FR (Completed) BE (Completed) HU (Completed) LT (Completed) CZ (Completed) EE (Completed) IT (Completed) GR (Prematurely Ended) BG (Completed) LV (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001008-49 | Sponsor Protocol Number: NV22155 | Start Date*: 2016-09-30 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche AG | |||||||||||||
Full Title: A randomized, multicenter trial of oseltamivir doses of 75 mg for 5 or 10 days versus 150 mg for 5 or 10 days in influenza patients with pandemic (H1N1) 2009 | |||||||||||||
Medical condition: Influenza | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014365-12 | Sponsor Protocol Number: WP22849 | Start Date*: 2010-01-26 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: Evaluación prospectiva en régimen abierto de la farmacocinética, la farmacodinamia y la seguridad de oseltamivir (Tamiflu®) en el tratamiento de lactantes de menos de 12 meses con infección gripal ... | |||||||||||||
Medical condition: Tratamiento de la gripe. Treatment of influenza. | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) FR (Completed) DE (Completed) GB (Completed) BE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002473-47 | Sponsor Protocol Number: NV20235 | Start Date*: 2007-01-25 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A double blind, randomized, placebo controlled, multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in immunocompromised patients | |||||||||||||
Medical condition: Seasonal prophylaxis of influenza in immonucompromised subjects | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) LT (Completed) FR (Completed) CZ (Completed) BE (Completed) EE (Completed) IT (Completed) PL (Ongoing) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002633-11 | Sponsor Protocol Number: NV25719 | Start Date*: 2013-01-24 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: An open label, randomised, adaptive, multicenter, pharmacokinetic/pharmacodynamic, phase Ib, study of oseltamivir (Tamiflu®) in the treatment of influenza in immunocompromised children, between 0-1... | |||||||||||||
Medical condition: Treatment of influenza in immunocompromised paedriatric patients. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) FI (Completed) IT (Completed) PL (Completed) BE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012367-34 | Sponsor Protocol Number: BCX1812-301 | Start Date*: 2009-11-27 | |||||||||||
Sponsor Name:BioCryst Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard o... | |||||||||||||
Medical condition: Influenza | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) NL (Ongoing) LV (Prematurely Ended) CZ (Completed) DE (Prematurely Ended) HU (Completed) GB (Prematurely Ended) SK (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000696-20 | Sponsor Protocol Number: 1719T0834 | Start Date*: 2020-03-31 |
Sponsor Name:Shionogi & Co., Ltd. | ||
Full Title: A phase 3 randomized, double-blind, placebo-controlled study to confirm the efficacy of a single dose of baloxavir marboxil in the prevention of influenza virus infection | ||
Medical condition: Influenza | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-002217-59 | Sponsor Protocol Number: 63623872FLZ3002 | Start Date*: 2018-05-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, ... | |||||||||||||
Medical condition: Influenza A Infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) LV (Prematurely Ended) EE (Completed) LT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) SK (Prematurely Ended) HU (Prematurely Ended) BE (Completed) BG (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004056-37 | Sponsor Protocol Number: MV40618 | Start Date*: 2019-10-17 | ||||||||||||||||||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||
Full Title: A PHASE IIIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL EFFICACY STUDY OF BALOXAVIR MARBOXIL FOR THE REDUCTION OF DIRECT TRANSMISSION OF INFLUENZA FROM OTHERWISE HEALTHY P... | ||||||||||||||||||||||||||||
Medical condition: Influenza | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Temporarily Halted) GB (GB - no longer in EU/EEA) GR (Completed) HU (Completed) PL (Completed) FR (Completed) BG (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-001611-30 | Sponsor Protocol Number: AJAE1001 | Start Date*: 2006-08-22 |
Sponsor Name:Hammersmith Hospital NHS Trust | ||
Full Title: Clinical trial comparing the effect of Acetaminophen and Ibuprofen on the duration of influenza viral shedding in young children (Pilot study) | ||
Medical condition: Influenza in children [positive rapid diagnostic test (QuickVue influenza test)confirmed by influenza PCR] Infants and young children shed the influenza virus for longer periods than adults, durat... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2018-002154-70 | Sponsor Protocol Number: CP40559 | Start Date*: 2019-10-24 | ||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||
Full Title: A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BALOXAVIR MARBOXIL IN OTHERWISE HEALTHY PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 1 YEAR WITH IN... | ||||||||||||||||||||||||||||
Medical condition: Influenza | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: PL (Completed) ES (Ongoing) FI (Completed) BG (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003002-17 | Sponsor Protocol Number: 63623872FLZ2002 | Start Date*: 2015-11-17 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult and Elderly H... | |||||||||||||
Medical condition: Influenza A virus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) DE (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002156-84 | Sponsor Protocol Number: 63623872FLZ3001 | Start Date*: 2018-05-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, a... | |||||||||||||
Medical condition: Influenza A Infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) SK (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001416-30 | Sponsor Protocol Number: CP40617 | Start Date*: 2018-12-12 | ||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||
Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL IN COMBINATION WITH STANDARD-OF-CARE NEURAMINIDASE INHIBITOR IN... | ||||||||||||||||||||||||||||
Medical condition: INFLUENZA | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BG (Completed) EE (Completed) CZ (Completed) SE (Completed) BE (Completed) DE (Completed) FR (Completed) FI (Completed) HU (Completed) ES (Completed) RO (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-001588-63 | Sponsor Protocol Number: 200925 | Start Date*: 2020-10-23 |
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
Full Title: An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neon... | ||
Medical condition: Influenza | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: PL (Prematurely Ended) GB (GB - no longer in EU/EEA) NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002512-40 | Sponsor Protocol Number: 201023 | Start Date*: 2016-12-05 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin (GSK1325756) co-administered with a standard-of-care antiviral (oseltamivir), in the treatment of adults hospit... | |||||||||||||
Medical condition: Hospitalized influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) ES (Completed) NL (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021621-12 | Sponsor Protocol Number: NAI114373 | Start Date*: 2010-12-01 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: NAI114373: A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of ... | |||||||||||||
Medical condition: hospitalised adults and adolescents with influenza | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) DE (Completed) FR (Completed) GB (Completed) HU (Completed) NL (Completed) CZ (Completed) NO (Completed) DK (Completed) GR (Completed) BE (Completed) PL (Completed) ES (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001026-22 | Sponsor Protocol Number: 1813T0835 | Start Date*: 2021-03-05 |
Sponsor Name:Shionogi & Co., Ltd. | ||
Full Title: An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Baloxavir Marboxil 2% Granules after Administration of a Single Dose to Otherwise Healthy Pediatric Patient... | ||
Medical condition: Influenza | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-004068-39 | Sponsor Protocol Number: VX14-787-103 | Start Date*: 2014-12-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combi... | |||||||||||||
Medical condition: Influenza A | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
